%0 Journal Article
%T Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It.
%A McGonagle K
%A Dematt EJ
%A Mi Z
%A Biswas K
%A Schroeck FR
%J Bladder Cancer
%V 10
%N 2
%D 2024
%M 39131873
%F 1.449
%R 10.3233/BLC-230099
%X <B>BACKGROUND: </B>The National Cancer Institute SEER Program regularly publishes bladder-cancer specific survival statistics. However, this data is for all bladder cancers, and information for non-muscle invasive bladder cancer (NMIBC) is difficult to obtain.<BR><B>OBJECTIVE: </B>To quantify 5-year overall and bladder cancer-specific survival in a cohort of Department of Veterans Affairs (VA) patients diagnosed with NMIBC.<BR><B>METHODS: </B>We identified VA patients diagnosed with NMIBC who underwent a transurethral resection from 2003-2013. The patient demographics and Charlson Comorbidity Index were categorized. We acquired the patients' date of death from the Veterans Health Administration's Death Ascertainment File and their cause of death from the Mortality Data Repository. We calculated Kaplan Meier estimates of survival.<BR><B>RESULTS: </B>A total of 27,008 patients were included; median age was 69 and almost all were male (99%). The median comorbidity score was 4. The most prevalent comorbidity indicators included Chronic Pulmonary Disease (48%), cancer other than Bladder (41%), and diabetes (40%). This cohort was found to have a 5-year overall survival of 68% (99% CI 67% -69%) and a 5-year bladder cancer-specific survival of 93% (99% CI 92% -94%).<BR><B>CONCLUSIONS: </B>The 5-year bladder cancer-specific survival in patients diagnosed with non-muscle invasive bladder cancer is substantially higher than the 5-year overall survival. This difference may be related to the severity and number of comorbidities that patients in this population must manage. This warrants further research into the necessity of currently recommended high-intensity cancer surveillance for individuals with NMIBC.